Inspire Medical Systems (NYSE:INSP) and Lucid Diagnostics (NASDAQ:LUCD) Financial Analysis

Inspire Medical Systems (NYSE:INSPGet Free Report) and Lucid Diagnostics (NASDAQ:LUCDGet Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Valuation & Earnings

This table compares Inspire Medical Systems and Lucid Diagnostics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inspire Medical Systems $624.80 million 11.52 -$21.15 million ($0.74) -320.88
Lucid Diagnostics $2.43 million 13.56 -$52.67 million ($1.27) -0.54

Inspire Medical Systems has higher revenue and earnings than Lucid Diagnostics. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Inspire Medical Systems and Lucid Diagnostics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inspire Medical Systems 0 4 10 0 2.71
Lucid Diagnostics 0 0 2 0 3.00

Inspire Medical Systems currently has a consensus target price of $272.20, suggesting a potential upside of 14.63%. Lucid Diagnostics has a consensus target price of $2.75, suggesting a potential upside of 302.58%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Inspire Medical Systems.

Volatility & Risk

Inspire Medical Systems has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.

Profitability

This table compares Inspire Medical Systems and Lucid Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inspire Medical Systems -3.39% -3.93% -3.38%
Lucid Diagnostics -2,169.07% -901.79% -121.11%

Institutional & Insider Ownership

94.9% of Inspire Medical Systems shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 4.1% of Inspire Medical Systems shares are owned by company insiders. Comparatively, 4.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Inspire Medical Systems beats Lucid Diagnostics on 8 of the 13 factors compared between the two stocks.

About Inspire Medical Systems

(Get Free Report)

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.